Incyte Corp. v. Granules India: Ruxolitinib Patent Consent Judgment
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Incyte Corporation v. Granules India, Ltd. |
| Case Number | 1:25-cv-13227 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jul 2025 – Feb 2026 210 Days |
| Outcome | Plaintiff Win — Permanent Injunction |
| Patents at Issue | |
| Accused Products | Samsung Galaxy S Series Smartphones |
| Accused Products | Samsung Galaxy S Series Smartphones |
| Accused Products | Generic Ruxolitinib Phosphate Tablets |
Case Overview
The Parties
⚖️ Plaintiff
Wilmington, Delaware-based biopharmaceutical company and the NDA holder for Jakafi® (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor.
🛡️ Defendant
Hyderabad-based global generic pharmaceutical manufacturer with significant ANDA filing activity across multiple therapeutic categories.
Patents at Issue
This landmark case involved five U.S. patents forming the core of Incyte’s assertion. These patents collectively span chemical composition, formulation, and related subject matter—a classic “patent thicket” surrounding a blockbuster drug.
- • US 7,598,257 — foundational compound patent covering ruxolitinib
- • US 8,415,362 — directed to ruxolitinib-related chemical compositions
- • US 8,722,693 — covering formulation or related chemical matter
- • US 8,822,481 — pharmaceutical composition claims
- • US 8,829,013 — pharmaceutical composition claims
Developing a generic drug?
Check if your pharmaceutical formulation might infringe these or related patents before ANDA filing.
The Verdict & Legal Analysis
Outcome
The New Jersey District Court entered a Consent Judgment and Permanent Injunction against Granules India on February 6, 2026. This outcome established significant precedent for how multi-patent pharmaceutical portfolios can deter generic market entry and protect blockbuster drug revenue. No monetary damages were specified, consistent with the injunctive-relief-focused nature of the consent judgment.
Key Legal Issues
The District Court’s analysis focused on the implications of a multi-patent portfolio in Hatch-Waxman litigation, where generic challengers assess litigation risk early and often elect settlement over prolonged contest. The broad injunction—covering Granules directly and preventing third-party assistance—signals Incyte’s intent to foreclose workaround commercialization strategies. This ruling reinforces the power of layered pharmaceutical patent estates to create durable competitive shields.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in generic drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 5 asserted patents and related patents in this drug space
- See which companies are most active in JAK inhibitor patents
- Understand claim construction patterns for chemical compositions
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for your generic ANDA
High Risk Area
JAK Inhibitor Formulations
5 Patents Directly Asserted
Plus many more in JAK inhibitor space
Complex Design-Around Options
Feasible with expert IP strategy
✅ Key Takeaways
Five-patent portfolios dramatically increase litigation costs for challengers, enabling early favorable settlements.
Search related case law →Injunctions extending to third-party infringers are increasingly standard in Hatch-Waxman consent judgments.
Explore precedents →Frequently Asked Questions
Five U.S. patents: Nos. 7,598,257; 8,415,362; 8,722,693; 8,822,481; and 8,829,013—covering ruxolitinib compound, composition, and formulation subject matter.
Granules India’s ANDA filing (No. 220521) referencing Incyte’s NDA 202192 triggered Hatch-Waxman infringement liability. The parties resolved the dispute via consent judgment before trial, with Granules accepting a permanent injunction.
It signals that Incyte’s patent portfolio presents significant litigation risk for generic challengers, potentially deterring future ANDA filers or encouraging early settlement approaches in similar disputes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Full-Text Database
- PACER Case No. 1:25-cv-13227
- FDA Orange Book – NDA 202192
- PatSnap — IP Intelligence Solutions for Pharma
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.